Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF by Kuhle, Jens et al.
Jens Kuhle
Raija L.P. Lindberg
Axel Regeniter
Matthias Mehling
Francine Hoffmann
Markus Reindl
Thomas Berger
Ernst W. Radue
David Leppert
Ludwig Kappos
Antimyelin antibodies in clinically isolated
syndromes correlate with inflammation in
MRI and CSF
Received: 31 January 2006
Received in revised form: 3 May 2006
Accepted: 11 May 2006
Published online: 26 February 2007
j Abstract Objective We inves-
tigated the correlation of anti-
myelin oligodendrocyte glycopro-
tein- (anti-MOG) and anti-myelin
basic protein antibodies (anti-
MBP) in serum of CIS patients with
inflammatory signs in MRI and in
CSF and, as previously suggested,
the incidence of more frequent and
rapid progression to clinically
definite MS (CDMS). Methods 133
CIS patients were analysed for
anti-MOG and anti-MBP (Western
blot). Routine CSF and cranial MRI
(quantitatively and qualitatively)
measures were analyzed. 55 pa-
tients had a follow-up of at least 12
months or until conversion to
CDMS. Results Patients with anti-
MOG and anti-MBP had an in-
creased intrathecal IgG production
and CSF white blood cell count
(p = 0.048 and p = 0.036). When
anti-MBP alone, or both antibodies
were present the cranial MRI
showed significantly more T2
lesions (p = 0.007 and p = 0.01,
respectively). There was a trend for
more lesion dissemination in anti-
MBP positive patients (p = 0.076).
Conversely, anti-MOG- and/or
anti-MBP failed to predict conver-
sion to CDMS in our follow-up
group (n = 55). Only in female
patients with at least one MRI
lesion (n = 34) did the presence of
anti-MOG correlate with more
frequent (p = 0.028) and more
rapid (p = 0.0209) transition to
CDMS. Conclusions Presence of
anti-MOG or anti-MBP or both
was not significantly associated
with conversion to CDMS in our
CIS cohort. However, patients with
anti-MOG and anti-MBP had
higher lesion load and more
disseminated lesions in cranial
MRI as well as higher values for
CSF leucocytes and intrathecal IgG
production. Our data support a
correlation of anti-MOG and anti-
MBP to inflammatory signs in MRI
and CSF. The prognostic value of
these antibodies for CDMS, how-
ever, seems to be less pronounced
than previously reported.
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Introduction
Approximately 90% of relapsing remitting multiple
sclerosis (MS) patients present with a clinically iso-
lated syndrome (CIS) as the initial feature of their
disease. Of these about 30–50% have symptoms and
signs referable to multi-focal disease (polysymptom-
atic) [43, 45] and 50–80% are found to have clinically
nonapparent cerebral white-matter lesions [30, 34].
Prognostic markers that allow for more accurate
information about the patients’ individual risk of
developing MS are important, as not all patients will
have a second episode defining conversion to clini-
cally definite MS (CDMS). Accurate prognosis would
influence treatment, because three randomized trials
have shown that the development of CDMS is delayed
by early interferon beta therapy [9, 19a].
Lesion load in the initial MRI of CIS patients has
been up to now the best validated prognostic para-
clinical measure [6, 24]. However, neither clinical nor
paraclinical markers (biofluid markers, MRI) have up
to now allowed the prediction of the course of MS in
an individual patient [1, 16]. In a recent report pa-
tients with serum anti-MOG antibodies (anti-MOG)
and anti-MBP antibodies (anti-MBP), determined by
Western blot, developed CDMS more often and earlier
than dual antibody-negative patients, suggesting that
the measurement of these antibodies is a useful tool
for predicting early conversion to CDMS [4].
There are several lines of evidence supporting a
role of antibody-mediated demyelination in MS [29,
41]. Myelin oligodendrocyte glycoprotein (MOG) is a
minor myelin component (0.01–0.05% of central
myelin protein) exclusively found in the CNS [28, 35].
It consists of a 122 amino acid (aa) glycosylated
n-terminal extracellular stretch, followed by a trans-
membranous (aa 123–150) and intracellular domain
(aa 151–218). The n-terminal domain is expressed on
the myelin surface, easily accessible to antibodies.
Besides inducing encephalitogenic T-cells, anti-MOG
lead to intensive demyelination in EAE [26, 38, 44].
Anti-MOG are capable of inducing demyelination in
brain cell cultures and have been detected in dis-
rupted myelin of MS patients [17, 21].
Myelin Basic Protein (MBP) constitutes about 30%
of the central myelin protein and is localised in cyto-
plasm [3]. It is an extensively investigated autoantigen.
The presence of antibodies against MBP in early MS is
well established but their pathogenicity or relation to
disease severity is still controversial [11, 37].
Using identical methods for antibody detection as
Berger et al. [4], we investigated an independent co-
hort of patients with CIS. We are reporting on the
relation of antibodies against myelin antigens with
MRI and CSF measures and conversion to CDMS.
Material and Methods
j Patients
To evaluate interlaboratory reproducibility prior to this study 39
sera of MS patients were analyzed for anti-MOG and anti-MBP
independently in Innsbruck (M. Reindl and T. Berger) and in our
laboratory using identical methods.
Subsequently we enrolled 60 CIS patients seen in our depart-
ment from 1998 to 2003 (Figure 1). The diagnosis of CIS was based
on the acute or subacute occurrence of a first clinical event sug-
gestive of MS lasting for at least 24 hours. Fatigue alone and
transient fever-related worsening of symptoms were not consid-
ered. Patients who had a history of any kind of previous neuro-
logical symptoms or clinical, laboratory, MRI, or CSF findings
suggestive of any diagnosis other than MS were excluded. Patients
were followed by visits at 6 or 12 month intervals including a
neurological examination and assessment for relapses to document
the interval between first clinical symptoms and CDMS. A diagnosis
of CDMS was established when new symptoms or exacerbation of a
previously stable or improving deficit at least four weeks after the
initial event persisting for more than 24 hours occurred. Minimal
follow-up was twelve months or the time point of CDMS diagnosis
(mean follow-up 32.9 months, SD: 19.9 months, range 12–77.2).
5/60 patients had no follow-up visit (four patients were lost to
follow-up and one refused a follow-up visit). Sera were drawn at the
earliest timepoint after initial presentation, stored at )80C and
examined retrospectively. The initial MRI of these patients was also
evaluated retrospectively.
We included additionally 73 patients from a prospective na-
tional Swiss project which offers practicing neurologists the eval-
uation of anti-MOG and anti-MBP status of their CIS patients
(Figure 1). Participating neurologists provided clinical information
in a standardized questionnaire.
j Image analysis
Hard copies of the MRI scans were re-evaluated centrally. High
quality and fully documented T2-, PD-weighted, FLAIR plane and
gadolinium-enhanced T1-weighted scans with 5mm slices per-
formed at 1.5 or 3 T were available for 109 of 133 patients. Two
experienced neuroradiologists, without access to the clinical
information or antibody status, assessed the scan quality and
eventually recorded the number and localization of detected
abnormalities. High signal lesions were counted per slice in T2-
A. 39 MS patients
- interlaboratory reproducibility
B. 60 CISpatients
- predictive value
- cross sectional comparison of
antibody results, clinical and MRI
findings
C. 73 CIS patients
- cross sectional comparison of
antibody results, clinical and MRI
findings
Fig. 1 Description of study populations. Prior to analyzing the CIS patient sera
(n = 133) for anti-MOG and anti-MBP 39 MS patient sera were analyzed for
interlaboratory reproducibility of the assay (A). The core study included 60 CIS
patients seen initially between 1998–2003 in our department and followed at
6 or 12 month intervals (B). In addition baseline findings of 73 CIS patients
from a prospective national Swiss project were correlated with clinical and MRI
characteristics (C)
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weighted SE and FLAIR images and categorized according to four
prespecified regions of the brain: 1. cortical/subcortical; 2. Corpus
callosum; 3. periventricular; 4. posterior cranial fossa.
Contrast enhancing lesions and black holes (low-signal lesions)
were also counted per slice on the enhanced T1-weighted images.
j Western blot analysis for anti-MOG and anti-MBP antibodies
The human recombinant extracellular MOG domain (aa 1–125) was
prepared as previously described [37]. Human myelin derived MBP
was commercially purchased (Chemicon).
In Western-blots either 15 lg recombinant MOG or 78 lg MBP
were loaded and separated in 10% BisTris (Nupage) sodium
dodecyl sulfate (SDS)-polyacrylamide gels (Novex, San Diego).
Separated proteins were electrotransferred to nitrocellulose mem-
branes (Hybond-C, Amersham). Efficiency of transfer was moni-
tored by the use of prestained low range SDS-PAGE standard
(Novex, SeeBlue Plus2) and by staining the membranes with Pon-
ceau S (Sigma, St. Louis) after transfer.
Blots were blocked with 2% milk powder in phosphate buffered
saline (PBS) containing 0.05% Tween-20 (PBS-T) for one hour, then
dried, cut into 2mm nitrocellulose strips and incubated overnight
at 4C with diluted human sera (1:500 in 2% milk powder in PBS-
T). The strips were then washed three times with PBS-T and
incubated with alkaline phosphatase conjugated anti-human IgM
(1:5000, Jackson) for 1 hour at room temperature. After washing
bound antibodies were detected by nitroblue tetrazolium chloride
and 5-bromo-4-chloro-3-indolyl phosphate (Roche Molecular
Diagnostics). The strips were then washed with distilled water,
dried, and then assessed independently by two investigators (R.L.;
F.H.) who had no access to clinical and MRI findings. A serum
sample was considered to be ‘‘positive’’ if the immunoreactivity
was greater than that of a standard ‘‘negative’’ control sample.
Monoclonal antibodies to MBP (MAB381, Chemicon), and MOG
(8.18-C5) [7], and positive and negative human serum samples
determined earlier were used as controls.
j Routine CSF examination
Cells were counted by phase contrast microscopy within one hour
after lumbar puncture. The reference limit was 4.0 cells/ll. Albumin
and IgG in CSF and corresponding serum were measured by
automated immunoprecipitation nephelometry and the CSF/serum
albumin ratio and IgG index (IgGCSF/IgGSerum):(albuminCSF/albu-
minSerum) calculated. Values > 0.7 reflect intrathecal IgG synthesis
[27]. The fraction (%) of intrathecally produced IgG was calculated
according to Reiber [36]. Oligoclonal IgG bands (OCB) were de-
tected by agarose isoelectric focusing combined with immuno-
blotting and avidin-biotin amplified double-antibody peroxidase
staining [20]. At least two sole OCB had to be present in CSF
without corresponding bands in serum [2].
j Statistical evaluation
Comparisons between groups according to antibody status were
performed with the chi-square, Mann-Whitney U-test or Fisher’s
exact test as appropriate. A two-tailed p < 0.05 was considered
statistically significant. The cumulative incidence of the develop-
ment of CDMS was calculated for the groups with Kaplan-Meier
estimates, and differences between the groups were evaluated with
the log-rank test. Incidence rates were compared by chi-square test.
The Cox proportional hazard model was used for univariate and
multivariate analysis, to estimate relative risks according to anti-
body status (hazard ratios and 95 percent confidence intervals (CI))
with adjustment for potential confounding variables.
Results
39 sera were analyzed independently in Innsbruck
(M. Reindl and T. Berger) and in our laboratory using
identical methods to evaluate interlaboratory repro-
ducibility. Strips were rated as ‘‘positive’’, and ‘‘neg-
ative’’ for anti-MOG- and anti-MBP antibodies. We
obtained concordant results in 88.5% of the anti-
MOG- and 85.2% of the anti-MBP-determinations.
We analysed 133 sera overall from patients with
CIS for anti-MOG and anti-MBP. The mean interval
from initial symptoms to blood draw was 119 days
(median 45 days, interquartile range: 106.5 days). The
mean age was 34.9 years (SD: 10.1, range: 13–62) and
the gender distribution was 73.7%/26.3% (f/m).
Symptoms occurring from spinal lesions were more
frequently observed than through involvement of
brainstem or optic tracts (37.6% vs. 18.0% and
18.8%). In 21.1% there was clinical evidence for
involvement of more than one anatomical region and
in 4.5% the initial symptom was not specified.
39.1% of the patients were single positive for anti-
MOG (n = 52), and 4.5% of the patients single positive
for anti-MBP (n = 6). 30.1% were anti-MOG and anti-
MBP double positive (n = 40) and 26.3% had no anti-
MOG or anti-MBP (double negative group, n = 35).
Women were overrepresented in the group that
scored positive for one or more antibodies: In the
anti-MBP or anti-MOG positive groups, 89.1% and
78.3% respectively were females, as compared with
65.5% and 63.4% in the anti-MBP or anti-MOG neg-
ative groups (p = 0.003 and 0.073). In the double
positive group, 87.5% were women, as compared with
57.1% in the double negative group (p = 0.003). Other
baseline variables like age, interval to blood draw,
type of initial symptoms and clinical state of disease
(relapse versus stable disease) did not relate to anti-
body status (Table 1).
30/128 (23.4%) patients lacked OCB and the fre-
quency of OCB did not relate to antibody status. By
contrast, quantitative CSF measures of inflammation
were increased in the antibody positive patients
(intrathecal IgG fraction: double negative group:
12.3%; double positive group: 28.3%, p = 0.048; CSF
leukocyte count (median): double negative group: 3.0
cells/ll; double positive group: 7.0 cells/ll, p = 0.036).
All patients had normal blood brain barrier function
as measured by age-adjusted albumin ratio values
(Table 2).
Since lesion load in MRI is associated with a higher
risk of conversion to MS we evaluated signs of
inflammation in the initial MRI in relation to anti-
body status. For 109 of 133 patients baseline MRIs
were available. Patients with anti-MOG and anti-MBP
showed more white matter lesions than patients
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without (p = 0.01, Figure 2a). This difference results
from higher lesion numbers in the anti-MBP positive
versus negative patients (p = 0.007, Figure 2b),
whereas such a correlation was not significant for
anti-MOG alone (p = 0.166, Figure 2c). Accordingly,
there was a trend towards lesion dissemination in
space being more pronounced in patients with anti-
MBP than in patients with anti-MOG (anti-MBP:
67.5% vs. 50.0% fulfilled Barkhof criteria, p = 0.076;
anti-MOG: 60.0% vs. 48.5%, p = 0.266). Moreover,
anti-MBP positive patients had more infratentorial
lesions than the remainder of patients (41.0% vs.
22.1%, p = 0.037). We saw no additional antibody
specific pattern of lesion distribution or preferential
lesion localization according to antibody status.
Clinical follow-up data was available from 55 pa-
tients (10 patients without anti-MOG or anti-MBP, 43
patients with anti-MOG, 26 patients with anti-MBP
and 24 patients with anti-MOG and anti-MBP).
Transition to CDMS occurred in 58% (32/55) of pa-
tients (mean duration: 14.6 months; SD: 9.7 months;
range: 1– 39 months), whereas 23 patients did not
experience a second clinical episode (mean follow-up
32.9 months, SD: 19.9 months, range 12–77.2
months).
Conversion to CDMS occurred more frequently in
patients with anti-MOG versus no anti-MOG (62.8%
vs. 41.7%), and anti-MBP versus no anti-MBP (69.2%
vs. 48.3%) and in patients positive for both antibodies
compared with those without any (75% vs. 50%) but
the differences did not reach significance (p>0.1 for
each of these comparisons). Only in female patients
with at least one T2 lesion did the difference between
antibody status and conversion to CDMS reach sig-
nificance for anti-MOG (n=34) (anti-MOG: 66.7%
vs. 14.3%, p = 0.028; anti-MBP: 66.7% vs. 43.8%, p =
0.3; double positive: 75.0% vs. 20.0%, p = 0.047)
(Table 3).
The Kaplan Meier analysis shows a trend towards
shorter time to second events in patients with at least
one inflammatory lesion and anti-MOG antibodies
(anti-MOG: 25.7 months, CI: 17.1–34.2; anti-MOG
negative: 47.8 months, CI: 26.2–69.3, p = 0.1062,
Figure 3b). In anti-MBP and double positive patients
this was even less significant (anti-MBP: 26.8 months,
CI: 16.5–37.0, anti-MBP negative: 37.4 months, CI:
22.7–52.2, p = 0.4886; double positive: 21.7 months,
CI: 13.7–29.8, double negative group: 39.6 months,
CI:15.8–63.4, p = 0.2102) and for anti-MOG with re-
gard to the entire follow-up group (anti-MOG: 30.3
Table 1 Baseline characteristics of the patients with CIS according to antibody status (groups B and C, Figure 1)
All patients Anti-MOG ) and Anti-MBP ) Anti-MOG + Anti-MBP + Anti-MOG + and Anti-MBP +
Patients, n (%) 133 35 (26.3) 92 (69.2) 46 (34.6) 40 (30.1)
Females, n (%) 98 (73.7) 20 (57.1) 72 (78.3)a 41 (89.1)a 35 (87.5)b
Age, years* 34.9 ± 10.1 35.1 ± 12.5 34.3 ± 8.9 34.8 ± 8.9 33.7 ± 8.3
Optic neuritis, n (%) 25 (18.8) 4 (11.4) 18 (19.6) 10 (21.7) 7 (18.9)
Brainstem, n (%) 24 (18.0) 4 (11.4) 19 (20.7) 11 (23.9) 10 (25.0)
Spinal, n (%) 50 (37.6) 18 (51.4) 31 (33.7) 12 (26.1) 11 (27.5)
> 1 region**, n (%) 28 (21.1) 8 (22.9) 19 (20.7) 10 (21.7) 9 (22.5)
Relapse, n (%) 45 (33.8) 10 (28.6) 33 (35.9) 16 (34.8) 14 (35.0)
Interval*, days 119 ± 186 97 ± 157 121 ± 190 116 ± 150 116 ± 150
* Values are means ± standard deviation. Significant findings are marked in bold.
** >1 anatomical region (multifocal first manifestation) [43].
a p = 0.073 and 0.003 for comparison with anti-MOG –/anti-MBP –; b p = 0.003 for comparison with anti-MOG – and anti-MBP –
Table 2 Cerebrospinal fluid findings according to antibody status (groups B and C, Figure 1)
All patients Anti-MOG ) and Anti-MBP ) Anti-MOG + Anti-MBP + Anti-MOG + and Anti-MBP +
Albumin ratio (n=70)* 5.2 ± 1.7 5.4 ± 1.8 5.0 ± 1.6 5.3 ± 1.6 5.2 ± 1.5
IgG-Index (n=70)* 0.98 ± 0.58 0.82 ± 0.56 1.03 ± 0.59 1.14 ± 0.70 1.16 ± 0.72a
Intrath. IgG (n=70) (%)* 21.6 ± 25.0 12.3 ± 23.3 24.2 ± 25.1 b 27.2 ± 27.6 28.3 ± 27.7c
Intrath. IgM (n=70) (%)* 2.6 ± 10.5 0.9 ± 3.2 3.2 ± 11.9 2.3 ± 10.2 2.6 ± 10.7
Intrath. IgA (n=70) (%)* 2.0 ± 8.7 0.0 ± 0.0 2.7 ± 9.9 1.3 ± 4.9 1.4 ± 5.2
Leuc./ll (n=114)** 4.3 ± 10.5 3.0 ± 10.3 6.0 ± 10.9 7.0 ± 5.4d 7.0 ± 5.5e
OCB pos. (n=128) (%) 76.6 78.8 75.6 80.0 80.0
* Values are means ± standard deviation. ** Values are medians ± standard deviation. Significant findings are marked in bold.
a p = 0.051 for comparison with anti-MOG – and anti-MBP –; b p = 0.056 for comparison with anti-MOG –; c p = 0.048 for comparison with anti-MOG – and anti-
MBP –; d p = 0.023 for comparison with anti-MBP –; e p = 0.036 for comparison with anti-MOG – and anti-MBP –
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months, CI: 21.8–38.8, anti-MOG negative: 44.3
months, CI: 23.9–64.7, p = 0.2801, Figure 3a). Again
only in female patients with at least one T2 hyperin-
tense lesion and anti-MOG or both antibodies did
CDMS develop significantly faster (anti-MOG: 27.5
months, CI: 17.5–37.4; anti-MOG negative: 64.5
months, CI: 44.1–84.8, p = 0.0209, Figure 3c; double
positive: 23.3 months, CI: 13.3–33.4, double negative:
58.1 months, CI:31.6–84.6, p = 0.0464). In the anti-
MBP positive group this was not visible (anti-MBP:
29.2 months, CI: 17.1–41.3; anti-MBP negative: 42.6
months, CI: 25.1–60.0, p = 0.2868).
The univariate Cox model confirmed that anti-
MOG and anti-MBP were not individual predictors
of CDMS in the entire patient group (p = 0.288 and
p = 0.359). Again, female patients with at least one
inflammatory lesion and anti-MOG showed a trend
for increased risk of developing CDMS (p = 0.051,
risk ratio: 7.5, CI: 0.1–57.0, n=34). In patients with
both antibodies this trend was also visible (p =
0.080, risk ratio: 6.4, CI: 0.8–51.4) but not in patients
with anti-MBP alone (p = 0.296, risk ratio 1.7, CI:
0.6–4.3).
The multivariate model included the initial symp-
toms, relapse or stable disease status at the timepoint
of blood drawing, the interval between first occur-
rence of symptoms and blood drawing, presence of
OCB and CSF-leukocyte count. In females with at least
one inflammatory lesion seropositivity for anti-MOG
but not anti-MBP was associated with a 28.5 fold risk
of CDMS compared with anti-MOG negative patients
(p = 0.005, risk ratio 28.5, CI: 2.7–300.4; anti-MBP: p
= 0.119, risk ratio 2.5, CI: 0.8–7.9). The same multi-
variate approach failed to show any significant prog-
nostic value of anti-MOG or anti-MBP positivity in
the overall patient group (n=55) (anti-MOG: p =
0.148, risk ratio 2.1, CI: 0.8–5.8; anti-MBP: p = 0.133,
risk ratio 1.8, CI: 0.8–3.8).
Discussion
There are no well established, reliable markers to
predict conversion of CIS to CDMS or to define sub-
sets of patients for potential early treatment. In a
previous study by Berger and colleagues, antibodies
against MOG and MBP in CIS patients were highly
predictive for CDMS. We aimed to confirm these
findings with samples of an independent CIS patient
cohort. We used Western blot technique to determine
IgM antibodies against the extracellular, non-gly-
cosylated MOG and purified human MBP used pre-
viously [4]. Our previous interlaboratory analysis
(Innsbruck vs. Basel) showed sufficient reproducibil-
ity of this technique.
The initial clinical presentation of MS affects dis-
ease course and prognosis without allowing reliable
individual long and especially short term predictions.
CIS patients with optic neuritis, isolated sensory
symptoms, long interval to second relapse and low
disability tend to have a better long-term prognosis
[10, 12, 22, 45].
Besides the fact that these clinical characteristics
allow limited long-term predictions, MRI has also
proven to be useful in estimating the interval to a
second relapse and consequently CDMS. We found
significantly more T2 hyperintense lesions in anti-
MBP alone or anti-MOG and anti-MBP positive pa-
tients compared to the other patient groups. In a
prospective study 72% of the 57 patients with
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Fig. 2 Number of T2 hyperintense lesions according to antibody status for
anti-MOG and anti-MBP- (a; n=62), anti-MBP- (b; n=109) and anti-MOG- (c;
n=109) negative and positive patients. Open bars denote AB-negativity, black
bars denote AB-positivity
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abnormal MRI (single asymptomatic lesion at base-
line) developed CDMS during a 5 year follow-up as
compared with 6% in the group of patients without
MRI lesions [31]. After 14 years 88% with an abnor-
mal baseline MRI developed CDMS whereas 19% with
normal baseline MRI had a second clinical event over
the same period [6]. In a cohort of 200 patients 49% of
patients with either four or more T2-weighted lesions
or three lesions, one of which had to be periventric-
ular, developed CDMS within 2 years, compared with
5% of patients who had a normal baseline MRI [24].
In another study 71% of 60 CIS patients with three or
more white matter lesions (at least one periventricu-
lar) progressed to CDMS after a mean follow-up of
14.3 months compared to only 24% of those without
lesions [39].
In our study the frequency of OCB was not related to
the myelin antibody status, but the amount of intra-
thecal IgG production and the CSF leukocyte counts
were significantly higher in the anti-MOG and anti-
MBP positive patients. In previous studies increased
intrathecal IgG concentrations and plasma cells were
associated with a more active disease course [13]. In a
group of 45 untreated patients with acute monosymp-
tomatic optic neuritis a significant relation was found
between leukocyte count and MRI as well as for IgG-
index and MRI lesions, but not between results of MRI
and presence of OCB [14]. An increased ratio between B
cells and monocytes in CSF was indicative of a pro-
nounced disease progression in patients with relapsing
remitting MS [8]. The specificity of the augmented
intrathecal B cell response in more active disease
courses is unclear and it is still doubtful if this relates to
intrathecally enriched anti-myelin antibody secreting
cells [33, 42]. Our findings of increased intrathecal IgG
production and increased leukocyte counts in the anti-
MOG and anti-MBP positive patients are in line with
previous reports on the role of humoral factors in the
progression of multiple sclerosis.
There have been several studies focusing on disease
specificity of anti-MOG rather than on prognostic value
in CIS patients. Although the pathogenic role of the
anti-MOG antibody response is well established in
animal models and in vitro, there is still no evidence in
MS [18, 21, 26]. The anti-MOG antibody response is
unlikely to be a specific feature of MS, since it also has
been detected in acute viral and bacterial CNS diseases.
In the latter cases the antibody response seems to be
transient, in contrast to its persistence in MS [37].
Lampasona and colleagues reported anti-MOG IgM
antibodies at a very low frequency in patients with MS,
encephalomyelitis and healthy control subjects (8%)
with no differences between groups using a liquid-
phase radiobinding assay (RIA). The antigen they used
was full-length, non-glycosylated MOG (amino acids
1)218) [23]. Gaertner et al. used an ELISA technique
with full-length, glycosylated mouse MOG and found
elevated levels of antibodies in serum in CIS and in
clinically active disease compared with healthy con-
trols [15]. However, no other inflammatory, neuro-
logical diseases were studied. For assay specificity the
glycosylation state of proteins, which affects confor-
mation must be taken into account, since glycosylated
proteins preserve their tertiary structure better than
unglycosylated ones [40]. In the assay we used, as
opposed to liquid-phase RIA, the antigen is immobi-
lized on a membrane. We can not exclude loss of
epitopes due to protein denaturation or exposure of
new epitopes not present in the native conformation
[32]. Liquid phase assays, in which a protein more
likely retains its original conformation, in contrast to
Western blot and ELISA techniques, might be an ap-
proach to study conformation dependent antibodies
and their possible disease specificity [5, 23].
Lim and colleagues recently investigated the
prognostic role of anti-MOG and anti-MBP in a co-
hort of 47 patients with CIS. Antibodies were analyzed
by applying Western blot as described by Berger et al.
[4]. It was noteworthy that 46 of the patients pre-
sented with optic neuritis and one patient had spinal
cord involvement. In this study baseline antibody
status did neither relate to the development of CDMS
Table 3 Characteristics of patients with follow-up (group B, Figure 1)
All patients Anti-MOG – and Anti-MBP ) Anti-MOG + Anti-MBP + Anti-MOG + and Anti-MBP +
Patients, n (%) 55 10 (18.2) 43 (78.2) 26 (47.3) 24 (43.6)
Females, n (%) 43 (78.2) 6 (60.0) 35 (81.4) 23 (88.5) 21 (87.5)
Time to diagnosis (mths)* 14.6 15.6 14.4 15.3 15.3
Duration of follow-up (mths)a* 32.9 30.5 32.1 41.0 39.4
Patients with CDMS, n (%) 32 (58.2) 5 (50.0) 27 (62.8) 18 (69.2) 18 (75.0)
- one T2 lesion, n (%)b 27 (60.0) 4 (44.4) 23 (67.6)d 15 (71.4) 15 (78.9)e
- females, one T2 lesion, n (%)c 19 (55.9) 1 (20.0) 18 (66.7)f 12 (66.7) 12 (75.0)h
* Values are means. Significant findings are marked in bold. a Duration of follow-up in patients without CDMS. b Patients with at least one T2 lesion in the baseline
MRI (n=45). c females with at least one T2 lesion in the baseline MRI (n=34)
d p=0.086 for comparison with anti-MOG – (36.4%); e p=0.097 for comparison with anti-MOG – and anti-MBP –
f p=0.028 for comparison with anti-MOG – (14.3%); h p=0.047 for comparison with anti-MOG – and anti-MBP –
165
after a follow-up of one year, nor was there any
association with MRI findings at baseline or after
follow-up [25].
In our study patients with anti-MOG and anti-
MBP developed CDMS more frequently (75%) than
patients without these antibodies (50%), without
reaching statistical significance. In a secondary
exploratory analysis approach this was more pro-
nounced in females with at least one T2 lesion.
Berger et al. exlusively included patients who had at
least two subclinical MRI lesions and OCB in the
CSF. Since we quantified lesions per slice to con-
sider spatial extension of lesions instead of real le-
sions it is difficult to compare the amount of
abnormality in MRI between these two studies.
Exclusion of patients without OCB from our follow-
up group (n=11) did not yield an increased asso-
ciation between anti-MOG or anti-MBP and CDMS
(data not shown). Importantly the gender distribu-
tion in the previous study by Berger et al. was
similar to our follow-up group (70.9% vs. 78.2%
respectively) excluding a major gender driven effect.
In the study by Berger et al serum samples for
antibody analysis were collected within two weeks
after the onset of the initial neurologic symptom [4].
Although in our patients we have not found differ-
ences in the risk of MS related to the interval of first
symptoms to blood draw (data not shown), the
delay of 119 ± 186 days in our study might have
had an impact on the results. Although our study is
not definitive due to the relatively low number of
patients involved (33/55 patients converted to
CDMS) and the limited duration of follow-up (mean
32.9 months), it supports the view that the prog-
nostic value of anti-MOG and anti MBP antibodies
is at best lower than initially indicated [4]. Studies
with longer and systematic clinical and MRI follow-
up in larger cohorts are needed to define more ex-
actly the role of anti-myelin antibodies in predicting
conversion to CDMS in CIS in general, or in well
characterized patient subgroups.
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Fig. 3 Cumulative probability of clinically definite multiple sclerosis
(CDMS) according to presence of anti-MOG antibodies in all patients with
follow up (a, n = 55), patients with at least one T2 lesion in MRI at
baseline (b, n = 45) and females with at least one T2 lesion in MRI at
baseline (c, n = 34)
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